Novartis AG
Profile managed by Bizz IdDescription
Products
19 productsFXI inhibitor. Atrial fibrillation (stroke prevention). Phase 3 (planned filing 2028).
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Proleukin. Oncology.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Simulect. For injection.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Beovu. Intravitreal injection.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Ilaris. Immunology and dermatology; subcutaneous injection.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Adakveo. P-selectin inhibitor; intravenous injection. Sickle cell disease, pediatrics in Phase 3.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Aimovig. CGRP receptor antagonist; subcutaneous injection. Migraine, pediatrics in Phase 3.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
IL-15 mAb. Atopic dermatitis and vitiligo. Phase 2.
Under development
Finished product (FDF)
Verified on 2026-10-21
VAY736. BAFF-R inhibitor, ADCC-mediated B-cell depletor. Sjögren's disease in registration; lupus nephritis, SLE, immune thrombocytopenia and warm autoimmune hemolytic anemia in Phase 3; systemic sclerosis in Phase 2.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Extavia.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
VHB937. TREM2 stabilizer and activator. Alzheimer's disease and amyotrophic lateral sclerosis. Phase 2.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Arzerra.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Kesimpta. CD20 antagonist; subcutaneous injection; neuroscience. Multiple sclerosis (new dosing regimen, pediatrics) in Phase 3.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Xolair. Immunology and dermatology; subcutaneous injection.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
PAC001. Anti-IL-6 mAb. Atherosclerotic cardiovascular disease and thyroid eye disease. Phase 2.
Under development
Finished product (FDF)
Verified on 2026-10-21
Anti-CD19, anti-CD2, anti-CD3. Rheumatoid arthritis and systemic lupus erythematosus. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Lucentis. Ophthalmology.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Cosentyx. IL-17A inhibitor; subcutaneous injection. Polymyalgia rheumatica in registration.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Anti-APRIL monoclonal antibody. IgA nephropathy. Phase 3 (planned filing 2027).
Under development
Finished product (FDF)
Verified on 2026-10-21